(PDF) Clinical Modality of Resistance and Subsequent

Clinical Modality of Resistance and Subsequent Management of Patients With Advanced Non-Small Cell Lung Cancer Failing Treatment With Osimertinib

Targeted Oncology - France

doi 10.1007/s11523-019-00644-6

Full Text

Abstract

Available in full text

Categories

Cancer Research

Date

May 23, 2019

Authors

Publisher

Springer Science and Business Media LLC

Related search

Management of Patients With Advanced Non-Small Cell Lung Cancer: Role of Gefitinib

Biologics: Targets and Therapy

Gastroenterology

English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Cancer Research

English

P3.01-100 Risk of Gastrointestinal and Hepatic Toxicities in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Osimertinib

Journal of Thoracic Oncology

Respiratory Medicine

English

Targeting HER2 Aberrations in Non-Small Cell Lung Cancer With Osimertinib

Clinical Cancer Research

Cancer Research

English

P2.13-42 Osimertinib Treatment for Patients With EGFR Exon 20 Insertion Positive Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer

Journal of Experimental and Clinical Cancer Research

Cancer Research

English

Circadian Function in Patients With Advanced Non-Small-Cell Lung Cancer

British Journal of Cancer

Cancer Research

English

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

Osimertinib 160 Mg Daily for Advanced Non‐small Cell Lung Cancer With Leptomeningeal Metastasis: A Case Report

Asia-Pacific Journal of Clinical Oncology

English